Literature DB >> 7478556

Selection of activating mutations of c-fms in FDC-P1 cells.

H R Glover1, D A Baker, A Celetti, N J Dibb.   

Abstract

FDC-P1 haemopoietic cells were used to select mutations of c-fms that constitutively activate the receptor for macrophage-colony stimulating factor (M-CSF or CSF-1). One mutation changed Ser 929 to Gly within a Ser/Gly rich region of the C-terminal tail and a second changed a nearby, highly conserved Leu 926 for Pro. A third mutation (D802V) changed Asp 802 to Val within the alpha L12/beta 9 region of the tyrosine kinase domain, so supporting the crystallographic evidence that this region triggers kinase activation. A c-kit mutation exactly equivalent to D802V was previously identified in a leukamic cell line and was demonstrated here to be transforming. Surprisingly, although D802V potently transformed FDC-P1 cells, it could not induce Rat-2 fibroblast foci, even in the presence of M-CSF. It is suggested that the accelerated receptor degradation induced by D802V may account for its cell specific effect.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7478556

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  3 in total

1.  Different pathways of colony-stimulating factor 1 degradation in macrophage populations revealed by wortmannin sensitivity.

Authors:  V Kanagasundaram; E Christy; J A Hamilton; A Jaworowski
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

2.  CSF1R mutations in hereditary diffuse leukoencephalopathy with spheroids are loss of function.

Authors:  Clare Pridans; Kristin A Sauter; Kristin Baer; Holger Kissel; David A Hume
Journal:  Sci Rep       Date:  2013-10-22       Impact factor: 4.379

3.  Differential effects of CSF-1R D802V and KIT D816V homologous mutations on receptor tertiary structure and allosteric communication.

Authors:  Priscila Da Silva Figueiredo Celestino Gomes; Nicolas Panel; Elodie Laine; Pedro Geraldo Pascutti; Eric Solary; Luba Tchertanov
Journal:  PLoS One       Date:  2014-05-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.